FATE - Fate Therapeutics Inc logo

Fate Therapeutics Inc

FATE

Fate Therapeutics develops cellular immunotherapies targeting cancer and immune disorders, including CAR T-cell and NK-cell therapies. Its product candidates aim to address various tumor types, B-cell lymphoma, and autoimmune diseases, enhancing treatment options.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$760today

Score Overview

1 Year
Score
Net Growth4.70%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-4.97%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.1
Net Growth38.77%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-88.69%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-288.22%
Net Trend30%
Net Income Consistency
Rev Growth43.48%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend23%
Net Income Consistency
Rev Growth6x
Rev Trend54%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Fate Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. FATE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 2.37โ€”
1 Year2025-09-30
$ 1.2688.10%
5 Years2021-09-30
$ 59.27-96.00%
10 Years2016-09-30
$ 3.12-24.04%
All Time2013-10-01
$ 6.62-64.20%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 6M-$ 129M$ 174M
2025$ 6M-$ 136M$ 203M
2024$ 13M-$ 186M$ 279M
2023$ 63M-$ 160M$ 315M
2022$ 96M-$ 255M$ 436M
2021$ 55M-$ 212M$ 615M
2020$ 31M-$ 173M$ 482M
2019$ 10M-$ 98M$ 221M
2018$ 4M-$ 66M$ 201M
2017$ 4M-$ 42M$ 100M
2016$ 4M-$ 33M$ 92M
2015$ 2M-$ 29M$ 64M
2014$ 0.00-$ 25M$ 49M
IPO2013$ 971K-$ 20M$ 54M
FATE - Fate Therapeutics Inc logo

Fate Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 31M to $ 6M and net income went from -$ 173M to -$ 136M. Revenue increased in 1 of those 5 years; net income in 3.

Across Fate Therapeutics Inc's full reported history, from 2013 to 2025, revenue grew from $ 971K to $ 6M and net income went from -$ 20M to -$ 136M. Revenue increased in 54% of the years measured; net income in 23%.

Fate Therapeutics Inc currently holds a 5-year HDB Score of 4.1 out of 10. How the HDB Score is calculated.

Membership

Explore FATE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies